Azeria Therapeutics Limited

Azeria is the world's first pioneer factor drug discovery company developing breakthrough treatments for hormone resistant breast and prostate cancer patients, where there are significant areas of unmet clinical need. Azeria is founded on the discoveries made by founder Dr Jason Carroll, a world leading expert in pioneer factors in cancer at his lab at the Cancer Research UK Cambridge Institute. Using its proprietary drug screening platform, Azeria is developing a pipeline of small molecules designed to selectively inhibit pioneer factors. Azeria is initially targeting the essential pioneer factor FOXA1, which has shown to be pivotal in the tumor development and maintenance of estrogen-receptor (ER) positive luminal breast cancer and is also thought to be critical in the development of prostate cancer.
Social Link - Linkedin: http://www. linkedin.com/company /azeria-therapeutics-limited
Employee Count: 3
Keywords: biotechnology